MedTrace Logo

Validation of Novel Predictive Score for Patients With Spinal Metastases

NCT03224650 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 219

Last updated 2022-03-02

No results posted yet for this study

Summary

The investigators are prospectively validating a prognostic clinical tool that uses a patient's modified Bauer grade, ambulatory status, and pre-operative serum albumin to predict survival, post-treatment morbidity, and functional outcomes in patients with metastatic disease involving the spine.

Conditions

  • Spinal Metastases

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Andrew Schoenfeld, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2020-07-13
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03224650 on ClinicalTrials.gov